Skip to main content
. Author manuscript; available in PMC: 2019 May 7.
Published in final edited form as: Mol Pharm. 2018 Apr 2;15(5):1766–1777. doi: 10.1021/acs.molpharmaceut.7b01013

Figure 3.

Figure 3

Effect of orally administrated MIDD0301 and salmeterol on airway hyperresponsiveness. Specific airway resistance (sRaw) was measured at increasing nebulized dosages of methacholine by DSI’s Buxco FinePointe noninvasive airway mechanics instrument (NAM). Ova s/c mice were administered vehicle or (A) 100 mg/kg, (B) 50 mg/kg, (C) 20 mg/kg of MIDD0301 via oral gavage b.i.d. for 5 days or (D) salmeterol also via oral gavage at 1 mg/kg b.i.d. for 5 days. Means ± SEM are presented for groups of 10 BALB/c mice. * and ** indicate p < 0.05 and p < 0.01 significance for the MIDD0301 group and •, ••, and ••• indicate p < 0.05, p < 0.01, and p < 0.001 significance between control mice compared to ova s/c mice using a two-way ANOVA repeated measures.